The requirement for robust analytical methods to characterize adeno-associated virus (AAV) vectors is immediate, as the field advances more AAV gene therapies into the clinic and onto commercialization. AAV capsid proteins (VPs) are critical for viral infectivity and vector potency. Thus, complete characterization of the constituent viral capsid proteins of AAV vectors, including their sequences and post-translational modifications (PTMs), is highly recommended to ensure AAV product quality and consistency. Typically, SDS-PAGE analysis followed by in-gel enzymatic digestion and liquid chromatography/tandem mass spectrometry (LC/MS/MS) is used for the characterization of viral capsid proteins. However, due to the limited recovery of digested peptides from the gel, determination of N-terminal sequences of VPs has not been reported to date. In this study, a direct liquid chromatography/mass spectrometry (LC/MS) intact protein analysis was developed to characterize viral capsid proteins in a variety of AAV serotypes. Both N- and C-terminal sequences of six AAV serotypes have been identified based on accurate mass measurement. This method can be used to confirm the identity of AAV serotype and monitor potential capsid protein heterogeneity. Complete sequence confirmation of AAV2 VPs was achieved through LC/MS/MS analysis of peptides generated using multiple enzymatic digestions. LC/MS/MS analysis confirmed the sequences for both N- and C-termini of capsid VPs and revealed acetylation on the N-termini of VP1 and VP3, consistent with LC/MS intact protein analysis.
GaoG, VandenbergheLH, WilsonJM. New recombinant serotypes of AAV vectors. Curr Gene Ther, 2005; 5:285–297.
3.
LisowskiL, DaneAP, ChuK, et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014; 506:382–386.
4.
Van VlietK, MohiuddinY, McClungS, et al.Adeno-associated virus capsid serotype identification: analytical methods development and application. J Virol Methods, 2009; 159:167–177.
5.
AkacheB, GrimmD, PandeyK, et al.The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol, 2006; 80:9831–9836.
6.
ShenS, BryantKD, BrownSM, et al.Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem, 2011; 286:13532–13540.
7.
MichelfelderS, TrepelM. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet, 2009; 67:29–60.
8.
AsokanA, SchafferDV, SamulskiRJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther, 2012; 20:699–708.
9.
WhiteJD, ThesierDM, SwainJB, et al.Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther, 2011; 18:546–552.
10.
JohnsonFB, OzerHL, HogganMD. Structural proteins of adenovirus-associated virus type 3. J Virol, 1971; 8:860–863.
11.
RoseJA, MaizelJVJr, InmanJK, et al.Structural proteins of adenovirus-associated viruses. J Virol, 1971; 8:766–770.
12.
BullerRM, RoseJA. Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J Virol, 1978; 25:331–338.
13.
LubeckMD, LeeHM, HogganMD, et al.Adenovirus-associated virus structural protein sequence homology. J Gen Virol, 1979; 45:209–216.
14.
McPhersonRA, RoseJA. Structural proteins of adenovirus-associated virus: subspecies and their relatedness. J Virol, 1983; 46:523–529.
15.
BecerraSP, RoseJA, HardyM, et al.Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon. Proc Natl Acad Sci U S A, 1985; 82:7919–7923.
16.
UrabeM, DingC, KotinRM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther, 2002; 13:1935–1943.
17.
KashiwakuraY, TamayoseK, IwabuchiK, et al.Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol, 2005; 79:609–614.
18.
QingK, MahC, HansenJ, et al.Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 1999; 5:71–77.
19.
SanliogluS, BensonPK, YangJ, et al.Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol, 2000; 74:9184–9196.
20.
SummerfordC, BartlettJS, SamulskiRJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med, 1999; 5:78–82.
21.
KernA, SchmidtK, LederC, et al.Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol, 2003; 77:11072–11081.
22.
GirodA, WobusCE, ZadoriZ, et al.The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol, 2002; 83:973–978.
23.
StahnkeS, LuxK, UhrigS, et al.Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology, 2011; 409:77–83.
24.
BlekerS, SonntagF, KleinschmidtJA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol, 2005; 79:2528–2540.
25.
Popa-WagnerR, PorwalM, KannM, et al.Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol, 2012; 86:9163–9174.
26.
ZhongL, LiB, JayandharanG, et al.Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology, 2008; 381:194–202.
27.
SenD, BalakrishnanB, GabrielN, et al.Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep, 2013; 3:1832.
28.
SenD, GadkariRA, SudhaG, et al.Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods, 2013; 24:104–116.
29.
LiB, MaW, LingC, et al.Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum Gene Ther Methods, 2015; 26:211–220.
30.
XieQ, BuW, BhatiaS, et al.The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A, 2002; 99:10405–10410.
31.
DiMattiaMA, NamHJ, Van VlietK, et al.Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol, 2012; 86:6947–6958.
32.
NamHJ, LaneMD, PadronE, et al.Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol, 2007; 81:12260–12271.
33.
MurrayS, NilssonCL, HareJT, et al.Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry. J Virol, 2006; 80:6171–6176.
34.
SalganikM, VenkatakrishnanB, BennettA, et al.Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol, 2012; 86:11877–11885.
35.
StrobelB, MillerFD, RistW, et al.Comparative analysis of cesium chloride- and iodixanol-based purification of recombinant adeno-associated viral vectors for preclinical applications. Hum Gene Ther Methods, 2015; 26:147–157.
36.
SnijderJ, van de WaterbeemdM, DamocE, et al.Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by Orbitrap mass spectrometry. J Am Chem Soc, 2014; 136:7295–7299.
37.
PiersonEE, KeiferDZ, AsokanA, et al.Resolving adeno-associated viral particle diversity with charge detection mass spectrometry. Anal Chem, 2016; 88:6718–6725.
38.
GrimmD, KernA, PawlitaM, et al.Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther, 1999; 6:1322–1330.
39.
KuckD, KernA, KleinschmidtJA. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J Virol Methods, 2007; 140:17–24.
40.
TsengYS, VlietKV, RaoL, et al.Generation and characterization of anti-adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. J Virol Methods, 2016; 236:105–110.
41.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
42.
FerreiraA, SinjoanuRC, NicholsonA, et al.Abeta toxicity in primary cultured neurons. Methods Mol Biol, 2011; 670:141–153.
43.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
44.
MiyazakiJ, TakakiS, ArakiK, et al.Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene, 1989; 79:269–277.
45.
NiwaH, YamamuraK, MiyazakiJ. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 1991; 108:193–199.
46.
MartinJ, FrederickA, LuoY, et al.Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods, 2013; 24:253–269.
47.
BurnhamB, NassS, KongE, et al.Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors. Hum Gene Ther Methods, 2015; 26:228–242.
48.
PerkinsDN, PappinDJ, CreasyDM, et al.Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis, 1999; 20:3551–3567.
49.
KozakM. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res, 1987; 15:8125–8148.
50.
HwangCS, ShemorryA, VarshavskyA. N-terminal acetylation of cellular proteins creates specific degradation signals. Science, 2010; 327:973–977.
51.
GovindasamyL, PadronE, McKennaR, et al.Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol, 2006; 80:11556–11570.
52.
NgR, GovindasamyL, GurdaBL, et al.Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol, 2010; 84:12945–12957.
53.
PulicherlaN, KotaP, DokholyanNV, et al.Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. PLoS One, 2012; 7:e32163.
54.
YanZ, ZakR, LuxtonGWG, et al.Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol, 2002; 76:2043–2053.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
